Advertisement
Advertisement
April 11, 2022
Truvic’s Prodigy Thrombectomy System Receives FDA 510(k) Clearance
April 11, 2022—Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., announced that it has received FDA 510(k) clearance for the Prodigy thrombectomy system, which is designed for the treatment of peripheral vascular thrombus.
In the press release, Mike Buck, CEO of Truvic, and Fred Khosravi, Chairman and CEO of Imperative Care, commented on the clearance.
Mr. Buck stated, “We are excited to receive FDA clearance for our first thrombectomy system. We look forward to working with experts in the field to translate Prodigy’s novel design elements and features into superb clinical outcome. This represents our first regulatory milestone as part of our strategy to advance multiple programs designed to meet patients’ needs and bring more innovative technologies to the market, faster.”
Mr. Khosravi added, “Imperative Care and Truvic share a culture of innovation and intense commitment to the needs of patients. I am pleased that these common values continue to help propel our development programs toward elevation of patient care.”
Advertisement
Advertisement
